The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.
about
Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique backgroundRelationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to knowNonalcoholic fatty liver disease - A multisystem disease?Management of moderate to severe psoriasis in patients with metabolic comorbiditiesHepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability.Non-alcoholic fatty liver disease and psoriasis: So far, so near.Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis.Nuclear factor κB-inducing kinase activation as a mechanism of pancreatic β cell failure in obesity.Psoriasis comorbidities: complications and benefits of immunobiological treatmentHelicobacter pylori infection in psoriasis: results of a clinical study and review of the literature.Homocysteine plasma levels in psoriasis patients: our experience and review of the literature.Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis.Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis.The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis.Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis.Insulin resistance, serum insulin and HOMA-R.Psoriasis beyond the skin surface: a pilot study on the ocular involvement.T helper (Th)1, Th17 and Th2 imbalance in mesenchymal stem cells of adult patients with atopic dermatitis: at the origin of the problem.The effect of low-carbohydrates calorie-restricted diet on visceral adipose tissue and metabolic status in psoriasis patients receiving TNF-alpha inhibitors: results of an open label controlled, prospective, clinical study.
P2860
Q26765175-0D209201-1109-4B74-BA82-51643B71FC29Q26767276-CED6D90C-B32E-4702-AB3A-BEEBD7FCD856Q26998754-E53074F6-D7F0-424C-8BB5-A563C3D72377Q28079077-274EFD42-57E8-43AC-9CD1-55CBF81C4E15Q28087039-4EA06938-242D-495C-84A4-1C7B5ABEA43FQ30665173-6A8813CA-8E3F-42F3-93C3-742FD3B3ECF0Q35237307-7F776611-99B7-4DEC-A378-7551BFD72100Q35444953-9983D059-2E32-4A20-AB7A-7749D2D65C92Q35894344-362B8078-93C9-4C34-9DD3-72F89DB9DF97Q37540440-3CEEBE4E-0391-4397-B009-54BD4B8F90D1Q38390774-5F69F0A0-A54B-4815-88B5-A8712DB37239Q38391127-34714EC7-53A5-4488-8064-D2BCB556F3A0Q41068916-5EEA287F-D586-4400-89DD-FADE7A8E4BF2Q41150051-A12BEEC0-9F94-4F6B-A71A-ADBA6FD05F28Q42008371-536CBFFB-81AA-4158-9D34-C42167BDA6CBQ42340109-D9A51F75-2C9B-4E50-AB75-2EF4F39C8D65Q45384544-F8BB9011-D228-405B-B317-0A43F567C390Q48077360-EB427341-3F21-4EE4-956A-52EECDF78D6CQ51496285-07E0DFBB-FE50-44D0-BEEC-8CE76EC2FCE3Q51555800-6C5EF552-4922-48A2-B0B6-FE717A57B9F5
P2860
The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The effect of etanercept on he ...... bolic syndrome, and psoriasis.
@en
The effect of etanercept on he ...... bolic syndrome, and psoriasis.
@nl
type
label
The effect of etanercept on he ...... bolic syndrome, and psoriasis.
@en
The effect of etanercept on he ...... bolic syndrome, and psoriasis.
@nl
prefLabel
The effect of etanercept on he ...... bolic syndrome, and psoriasis.
@en
The effect of etanercept on he ...... bolic syndrome, and psoriasis.
@nl
P2093
P2860
P1476
The effect of etanercept on he ...... abolic syndrome, and psoriasis
@en
P2093
A Benedetti
A Campanati
A Offidani
G Ganzetti
L Sandroni
P2860
P304
P356
10.1007/S00535-012-0678-9
P577
2012-10-13T00:00:00Z